All In Biotech

Drug Trial Radar · NCT04669171

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jul 5, 2021

Primary completion

May 30, 2029

Study completion May 30, 2034

Sponsor

Lead sponsor
EnteromeIndustry
Sponsor type
Industry
First posted
Dec 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

Conditions

  • Follicular Lymphoma
  • Marginal Zone Lymphoma

Interventions

  • EO2463Biological

    Multiple dose of EO2463

  • lenalidomideDrug

    D1-21 of 4-weekly cycles

  • rituximabBiological

    Multiple doses of rituximab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |Time frame: Up to 24 months
  2. Phase 2: Overall Response RateTime frame: Up to 24 months
  3. Phase 2: Complete Response RateTime frame: Up to 24 months

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)

    Rochester, New York

  • University of Washington-Seattle Cancer Care Alliance

    Seattle, Washington

  • CHU d'Amiens-Picardie - Hopital SUD

    Amiens, France

  • IRCCS Policlinico San Matteo Foundation - University of Pavia

    Naples, Italy

  • IRCCS Policlinico San Matteo Foundation - University of Pavia

    Pavia, Italy

  • University Hospital Vall d'Hebron, Institute of Oncology

    Barcelona, Spain

  • Clinica Universidad de Navarra

    Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Hospital Clinico Universitario de Salamanca

    Salamanca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.